← All trials
NCT05473520
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 3, 2022
- Primary completion
- Oct 3, 2024
- Completion date
- Dec 27, 2024
- First posted
- Jul 26, 2022
- Last posted
- Sep 30, 2022
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National University of SingaporeLead sponsor
- Queen Elizabeth Hospital, Kota Kinabalu, Sabah, MalaysiaCollaborator
- National University of SingaporeCollaborator
- National University of SingaporeOverall official - principal investigator
- Nanyang Technological UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.